Mankind Pharma Ltd
NSE:MANKIND
Net Margin
Mankind Pharma Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| IN |
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
934.9B INR |
16%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
741.6B USD |
23%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
367.5B USD |
24%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.9T DKK |
35%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
208.6B CHF |
14%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
188.8B CHF |
24%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
158.5B GBP |
14%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
197.4B USD |
27%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
-126%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
137.8B USD |
13%
|
Mankind Pharma Ltd
Glance View
Mankind Pharma Ltd. has carved a unique niche in the pharmaceutical landscape of India, emerging as a formidable entity through an intriguing blend of affordability and accessibility. Founded in 1995 by R. C. Juneja, the company has steadily grown its portfolio to encompass a vast range of pharmaceutical products spanning prescription medications, over-the-counter (OTC) drugs, and consumer healthcare goods. Operating with a distinctive business model rooted in the ethos of delivering quality medicine at affordable prices, Mankind Pharma reaches deep into the densely populated tier II and tier III cities of India, ensuring that healthcare is accessible to the masses who need it the most. This strategic outreach, coupled with strong marketing and distribution networks, serves as a cornerstone of its business success. The company’s financial health is buoyed by its diversified product range, which caters to multiple therapeutic areas including antibiotics, cardiovascular, antifungal, and gastrointestinal, among others. Their robust R&D initiatives further reinforce their competitive edge, enabling them to continually introduce new and effective products that resonate with both healthcare providers and consumers. Revenue streams are not just confined to domestic borders; Mankind Pharma has been expanding its footprint internationally, penetrating markets across Asia, Africa, and the Americas. By striking a strategic balance between volume-driven pricing models and extensive market reach, Mankind Pharma not only emphasizes profitability but also solidifies its commitment to public health initiatives globally, thus creating a sustainable and progressive business trajectory.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Mankind Pharma Ltd's most recent financial statements, the company has Net Margin of 16.3%.
You don't have any saved screeners yet